Yuhan’s Leclaza enters US 6yrs after signing licensing deal
By Chon, Seung-Hyun | translator Kang, Shin-Kook
24.08.22 05:04:50
가나다라
0
FDA approved Leclaza+Rybrevant combination therapy…first domestically developed anticancer drug to enter the US
Secures USD 50 million upfront payment for licensing deal in 2018…Cumulative technology fee amounts to USD 210 million
Cumulative domestic sales of Leclaza KRW 61.7 billion...totals to over KRW 300 billion
Yuhan Corp’s new anticancer drug Leclaza has successfully entered the U.S. market. The drug has reached the commercialization stage 6 years after licensing out its technology to Janssen. As a result, the company will receive USD 60 million as a milestone payment with Leclaza’s approval in the U.S. The company has earned nearly KRW 300 billion in technology fees since licensing out Leclaza’s technology.
▲Yuhan Corp headquarters
According to industry sources on the 21st, Yuhan Corp’s new anticancer drug Leclaza received marketing authorization from the U.S. Food and Drug Administration (FDA) on the 20th. The U.S. Food and Drug Administration (FDA) has approved Yuhan Corporation’s Leclaza in combination with Johnson & Johnson
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)